Summary & Overview
HCPCS G8869: Hepatitis B Immunity Documented for Anti-TNF Initiation
HCPCS Level II code G8869 documents that a patient has confirmed immunity to hepatitis B at the time of initiating anti-TNF (tumor necrosis factor) therapy. This status is clinically important because anti-TNF agents can increase infection risk; documenting hepatitis B immunity informs treatment safety assessments and care coordination. Nationally, proper documentation supports clinical decision-making, infection prevention, and accurate billing for pre-treatment evaluation steps.
Key payers in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code's clinical role, how it aligns with the service of pre-treatment immunity verification, and where that service is typically performed. The publication also outlines benchmarking and policy considerations relevant to payers and providers: common payer coverage patterns, potential documentation requirements, and how G8869 fits into anti-TNF initiation workflows. The content is intended for clinicians, practice managers, and revenue cycle staff seeking a clear, national-level understanding of the code's purpose, common use cases, and implications for pre-biologic therapy processes.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, or related codes.
Billing Code Overview
HCPCS Level II code G8869 indicates that a patient has documented immunity to hepatitis B and is initiating anti-TNF therapy. This code represents a clinical status related to infectious disease immunity screening and documentation in the context of starting tumor necrosis factor inhibitor treatment.
-
Service type: Pre-treatment immunization/immunity documentation and clearance for biologic therapy
-
Typical site of service: Outpatient specialty clinic (for example, rheumatology, gastroenterology, dermatology) or infusion center where anti-TNF therapy is initiated
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with moderate to severe rheumatoid arthritis is being evaluated for initiation of anti–tumor necrosis factor (anti‑TNF) systemic therapy in a specialty rheumatology clinic. The clinician documents prior hepatitis B vaccination series and obtains laboratory confirmation of immunity (positive hepatitis B surface antibody). Before starting anti‑TNF therapy, the clinician reviews infectious risk, documents existing immunity to hepatitis B in the medical record, and completes pre‑treatment counseling and medication consent. The service is typically delivered in an outpatient specialty clinic (rheumatology or immunology) or infusion center during a pre‑treatment visit or at the time of first biologic administration. The clinical workflow includes chart review of immunization records, ordering or reviewing serologic testing if needed, documentation of immunity status in the electronic health record, and communicating findings to the prescribing provider and infusion nursing staff to proceed with anti‑TNF therapy without additional hepatitis B prophylaxis.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or complexity of documentation for pre‑therapy evaluation is substantially greater than typical. |
23 |